← Leaderboards
Patricia Ann Thompson-Carino
University Of Texas Md Anderson Can Ctr
$8,608,763
Attributed
$18,175,561
Total exposure
7
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.5M · FY2011–25$2.5M$1.9M$1.3M$625K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$18,175,561 · 7
By mechanism
R01$15,231,020 · 5
UG1$2,869,041 · 1
R03$75,500 · 1
Top collaborators
- Alison T Stopeck11 shared
- Melissa L Bondy5 shared
- Abenaa M Brewster5 shared
- Hyung L Kim3 shared
- M. Peter Lance3 shared
- Julie E Bauman2 shared
Most similar at University Of Texas Md Anderson Can Ctr
Same institution · by research overlap
- Bogdan A Czerniak$13,889,235
- Ralf Krahe$5,390,940
- Claudio Marcelo Aldaz$3,458,328
- Francis Ali-Osman$9,395,076
- Funda Meric-Bernstam$12,297,463
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsMalignant Breast NeoplasmTissuesTumorBiopsyCessation Of LifePreventFundingCancer RecurrenceBiological MarkersPharmaceutical PreparationsPre-Clinical ModelRandomizedRecurrenceClinical TrialsAnimalsBreastBreast Cancer ModelDrug UsageDoseMagnetic Resonance ImagingPostmenopauseMediatingMorbidity - Disease Rate
Grant awards (25)
University of Arizona Cancer Prevention Clinical Trials Network$1,747,889
UG1 · FY2025 · CA · contact PI
Intensive cholesterol-lowering intervention and anti-tumor immunity modeled in prostate cancer$692,001
R01 · FY2025 · CA
University of Arizona Cancer Prevention Clinical Trials Network (UA CP-CTNet)$1,121,152
UG1 · FY2024 · CA · contact PI
Intensive cholesterol-lowering intervention and anti-tumor immunity modeled in prostate cancer$657,403
R01 · FY2024 · CA
Three-Arm randomized trial comparing the effect of aspirin, sulindac or no treatment control on breast density in patients with elevated breast cancer risk$597,059
R01 · FY2024 · CA · contact PI
Three-Arm randomized trial comparing the effect of aspirin, sulindac or no treatment control on breast density in patients with elevated breast cancer risk$702,967
R01 · FY2023 · CA · contact PI
Intensive cholesterol-lowering intervention and anti-tumor immunity modeled in prostate cancer$692,001
R01 · FY2023 · CA
Three-Arm randomized trial comparing the effect of aspirin, sulindac or no treatment control on breast density in patients with elevated breast cancer risk$567,232
R01 · FY2022 · CA · contact PI
Three-Arm randomized trial comparing the effect of aspirin, sulindac or no treatment control on breast density in patients with elevated breast cancer risk$581,171
R01 · FY2020 · CA · contact PI
Three-Arm randomized trial comparing the effect of aspirin, sulindac or no treatment control on breast density in patients with elevated breast cancer risk$546,274
R01 · FY2019 · CA · contact PI
Risk Prediction for ER Negative Breast Cancer Recurrence$593,132
R01 · FY2017 · CA
Risk Prediction for ER Negative Breast Cancer Recurrence$614,362
R01 · FY2016 · CA
Nsaid Effects on Clinical and Imaging Breast Biomarkers$449,101
R01 · FY2016 · CA
Risk Prediction for ER Negative Breast Cancer Recurrence$624,192
R01 · FY2015 · CA
Nsaid Effects on Clinical and Imaging Breast Biomarkers$321,311
R01 · FY2015 · CA
Risk Prediction for ER Negative Breast Cancer Recurrence$603,134
R01 · FY2014 · CA
Nsaid Effects on Clinical and Imaging Breast Biomarkers$486,805
R01 · FY2014 · CA
Nsaid Effects on Clinical and Imaging Breast Biomarkers$138,298
R01 · FY2014 · CA
Selenium Colorectal Cancer Chemoprevention Trials$1,219,754
R01 · FY2013 · CA · contact PI
Risk Prediction for ER Negative Breast Cancer Recurrence$665,785
R01 · FY2013 · CA
Nsaid Effects on Clinical and Imaging Breast Biomarkers$584,187
R01 · FY2013 · CA
Selenium Colorectal Cancer Chemoprevention Trials$1,587,540
R01 · FY2012 · CA · contact PI
Nsaid Effects on Clinical and Imaging Breast Biomarkers$400,797
R01 · FY2012 · CA
Selenium Colorectal Cancer Chemoprevention Trials$1,906,514
R01 · FY2011 · CA · contact PI
BETA 2 ADRENERGIC RECEPTORS AND PROSTATE CANCER RISK$75,500
R03 · FY2000 · CA